Center for Precision Medicine for High-Risk Pediatric Cancer
The Center for Precision Medicine for High-Risk Pediatric Cancer is a unified “single stop” for children, adolescents and young adults whose cancers lack an effective standard of care, fail to respond to standard therapy or relapse after initial therapy.
The center focuses on comprehensive multi-omics profiling of each patient’s tumor to define the best treatment options for that patient. We utilize state-of-the-art next-generation sequencing and other omics platforms performed in the Division of Genomic Diagnostics’s cancer genomics lab to evaluate the genetic changes that drive the cancer. We integrate this tumor profiling with individual patient and tumor characteristics and any prior treatment to find a personalized treatment strategy.
The center brings together a multidisciplinary team of experts personalized for your child. We partner closely with our Developmental Therapeutics Program team to offer clinical trials of novel therapeutics in addition to standard chemotherapy, FDA-approved targeted therapies, surgery, radiation and interventional radiology procedures. We also partner closely with our Cell and Gene Therapy Collaborative to offer CAR T-cell therapies when appropriate. Through every phase of treatment, you’ll have access to a large, dedicated team of care providers who specialize in your child’s specific cancer and your family’s unique needs.
The Center for Precision Medicine for High-Risk Pediatric Cancer is a part of Children's Hospital of Philadelphia’s highly ranked Cancer Center. It is led by world-class experts in rare tumors, molecularly targeted therapy, and cancer genomic diagnostics.
Conditions We Treat
Relapsed/refractory cancers, including:
- Brain tumors
- Solid tumors
- Leukemia and lymphoma
- Rare cancers lacking a standard therapy